Testosterone therapy and cardiovascular events

Testosterone therapy, thrombosis, thrombophilia, cardiovascular events.

There are similar time intervals between starting testosterone therapy (TT) and development of thrombotic (~4.5 months) or cardiovascular (CVD) events (~3 months) which may, speculatively, reflect a shared pathophysiology. We have described thrombotic events 5 months (median) after starting TT in 38 men and 4 women, including 27 with deep venous thrombosis-pulmonary embolism, 12 with osteonecro...

Testosterone therapy and cardiovascular risk.

Endogenous testosterone levels are inversely associated with cardiovascular risk in older men and men with cardiovascular disease. Current data on cardiovascular outcomes of testosterone therapy include only observational studies and adverse event monitoring in short-term trials that were not designed to measure cardiovascular outcomes. These studies have yielded conflicting results, and some h...

Conclusions about testosterone therapy and cardiovascular risk

Testosterone treatment and cardiovascular events in prescription database studies

Over the past decade, there has been a substantial increase in the number of men who are treated with testosterone. Despite this increase in the use of testosterone, the risks of adverse cardiovascular events are unclear as meta-analyses have reported conflicting findings and no clinical studies have been large enough or long enough to adequately assess for cardiovascular risks. The goal of thi...

Deaths and cardiovascular events in men receiving testosterone.

Deaths and Cardiovascular Events inMenReceiving Testosterone To the Editor As clinicians and researchers in the testosterone field,we found surprising the results reportedbyDrVigenand colleagues1 of increased deaths and cardiovascular events in male veterans receiving testosterone following coronary angiography because these results contradict a literature spanningmore than20years.2 Should test...